Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CCR1 antagonists.

Jie-Fei Cheng1, Rick Jack

  • 1Tanabe Research Laboratories-USA, Inc., San Diego, CA 92121, USA. jcheng@trlusa.com

Molecular Diversity
|June 19, 2008
PubMed
Summary
This summary is machine-generated.

CC Chemokine receptor 1 (CCR1) antagonists show promise for treating inflammatory diseases. Despite early clinical trial setbacks, newer compounds demonstrate efficacy in animal models, driving continued research for autoimmune and inflammatory therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Toll-like Receptors 7, 8, and 9 Inhibition in Systemic Lupus Erythematosus: Therapeutic Advance and Future Directions.

Journal of medicinal chemistry·2026
Same author

Meta-analysis of transarterial chemoembolization combined with cryoablation <i>vs</i> transarterial chemoembolization alone for ≥ 5 cm hepatocellular carcinoma.

World journal of gastrointestinal oncology·2024
Same author

Correction for Oka et al., "<i>In Vitro</i> and <i>In Vivo</i> Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile<i>"</i>.

Antimicrobial agents and chemotherapy·2022
Same author

<i>In Vitro</i> and <i>In Vivo</i> Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.

Antimicrobial agents and chemotherapy·2021
Same author

The medicinal chemistry of new agents to treat diabetes and obesity.

Current topics in medicinal chemistry·2010
Same author

Two-dimensional turbulent flow chromatography coupled on-line to liquid chromatography-mass spectrometry for solution-based ligand screening against multiple proteins.

Journal of chromatography. A·2009
Same journal

Discovery of novel perillyl and myrtenyl nucleobase conjugates as dual anti-Alzheimer and antimicrobial agents.

Molecular diversity·2026
Same journal

Integrative network pharmacology and molecular modelling identify taxifolin as a potential modulator of melatonin receptor MT1 in mood disorders.

Molecular diversity·2026
Same journal

Design, synthesis and biological evaluations of novel VEGFR-2 inhibitors based on Fruquintinib and Cabozantinib.

Molecular diversity·2026
Same journal

Integrative subtractive genomics and molecular dynamics-based approach for drug repurposing against female genital tuberculosis.

Molecular diversity·2026
Same journal

Design, synthesis, and biological evaluation of novel isobenzofuran-1(3H)-one derivatives with antioxidant properties and improved oral bioavailability.

Molecular diversity·2026
Same journal

Benchmarking docking and ML re-scoring screening performance for KRAS G12D in pancreatic cancer.

Molecular diversity·2026
See all related articles

Area of Science:

  • Immunology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • CC Chemokine receptor 1 (CCR1) is a G protein-coupled receptor on leukocytes, crucial in inflammatory conditions.
  • CCR1 antagonism is a therapeutic strategy for autoimmune and inflammatory diseases.
  • Developing effective CCR1 antagonists faces challenges, including species cross-reactivity for in vivo studies.

Purpose of the Study:

  • To review the development and therapeutic potential of CCR1 antagonists.
  • To highlight advancements in CCR1 antagonist design and efficacy.
  • To discuss the ongoing evaluation of CCR1 antagonists in preclinical and clinical settings.

Main Methods:

  • Literature review of CCR1 antagonists.
  • Analysis of in vitro and in vivo study findings.

Related Experiment Videos

  • Examination of clinical trial outcomes.

    • Main Results:

    • Numerous CCR1 antagonists have been developed.
    • Improved compounds show promising in vivo efficacy in animal models.
    • Early clinical trials faced challenges, with some compounds withdrawn due to lack of efficacy.

    Conclusions:

    • CCR1 remains a viable therapeutic target for inflammatory and autoimmune diseases.
    • Recent advancements in CCR1 antagonist development offer renewed hope for clinical success.
    • Continued preclinical and clinical research is essential to realize the therapeutic potential of CCR1 antagonists.